Chuangsheng Group announced the completion of a new phase of clinical trials of TST001 combined with oxaliplatin and capecitabine

Chuangsheng Group, an international biopharmaceutical company in the clinical stage with the ability to integrate the entire process of biopharmaceutical R&D, clinical and process development and production, announced that it has completed TST001, a human source targeting Claudin 18.
2 (CLDN18.
2) Monoclonal antibody, combined with oxaliplatin and capecitabine, was administered to the first patient in a phase I clinical study of first-line locally advanced unresectable or metastatic gastric cancer
.

TST001 is a second-generation recombinant humanized monoclonal antibody candidate drug targeting CLDN18.
2 independently developed by Chuangsheng Group through its immune tolerance barrier breakthrough technology platform
.

"CLDN18.
2 has been shown to be abnormally expressed in many types of cancers, including gastric cancer, pancreatic cancer, and esophageal cancer
.

Dr.
Shi Ming, Executive Vice President, Head of Global R&D and Chief Medical Officer of Chuangsheng Group, said: “Gastric cancer is a high incidence tumor species in China and Asia
.